3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
44
Phase EARLY_PHASE1
5
Phase 2
5
Phase 4
2
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Melanoma
3
Breast Neoplasms
2
Thymic aplasia
1
Small Cell Lung Carcinoma
1
Pain, Postoperative
1
Neoplasms
1
Lung Neoplasms
1
Immunologic Deficiency Syndromes
1
Hematologic Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Letrozole
20
Docetaxel
16
Cyclophosphamide
13
Zoledronic Acid
12
exemestane
11
Trastuzumab
11
Anastrozole
11
Paclitaxel
10
Tamoxifen
9
Capecitabine
9
Fulvestrant
8
Epirubicin
8
pegfilgrastim
7
pertuzumab
6
liposomal doxorubicin
6
abemaciclib
6
Saline Solution
6
palbociclib
5
Sodium Chloride
5
Dexmedetomidine
5
Carboplatin
5
Bupivacaine
5
Bevacizumab
5
ribociclib
4
pegylated granulocyte colony-stimulating factor
4
eribulin
4
Tranexamic Acid
4
Standard of Care
4
Pamidronate
4
Filgrastim
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Breast Neoplasms
×
Blood Specimen Collection
×
Clear all
NCT06274515
2026-05-06
REMERGE
Hoffmann-La Roche
Phase 4
Recruiting
320 enrolled
NCT07490509
2026-04-01
DOSABEMA
Poitiers University Hospital
Phase 4
Not yet recruiting
235 enrolled